Halozyme to Present at the UBS Global Life Sciences Conference

SAN DIEGO--(BUSINESS WIRE)--Sep. 15, 2009-- Halozyme Therapeutics, Inc. (Nasdaq:HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced its participation in the UBS Global Life Sciences Conference to be held on September 21-23, 2009 in New York City. Jonathan Lim, M.D., President and CEO, is scheduled to present an overview of Halozyme and its product development pipeline on Tuesday, September 22, 2009 at 3:00 p.m. EDT (12:00 p.m. PDT).

To listen to the audio webcast of the presentation live or after the event, please visit the company's Web site at https://www.halozyme.com. The replay will be available for 30 days after the presentation.

About Halozyme Therapeutics, Inc.

Halozyme is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the endocrinology, oncology, dermatology and drug delivery markets. The company's portfolio of products and product candidates is based on intellectual property covering the family of human enzymes known as hyaluronidases and additional enzymes that affect the extracellular matrix. Halozyme's Enhanze™ Technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. The company has key partnerships with Roche to apply Enhanze Technology to Roche's biological therapeutic compounds for up to 13 targets and with Baxter BioScience to apply Enhanze Technology to Baxter's biological therapeutic compound, GAMMAGARD LIQUID™. The product candidates in Halozyme's research pipeline target multiple areas of significant unmet medical need. For more information visit https://www.halozyme.com.

Source: Halozyme Therapeutics, Inc.

HalozymeRobert H. UhlSenior Director, Investor [email protected]